Related and Nonrelated Parties [Axis] Related Party [Member] Nonrelated Party [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Series A-2 Convertible Preferred Stock [Member] Series A-3 Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Business Combination [Axis] NanoSynex, Ltd. [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Subscription Agreement [Member] Amendment and Settlement Agreement [Member] Legal Entity [Axis] IR Agency LLC [Member] Crypto Asset [Axis] Cardano ADA (ADA) [Member] Native BNB (BSC) [Member] Bitcoin (BTC) [Member] Dogecoin (DOGE) [Member] Ethereum (ETH) [Member] ChainLink (LINK) [Member] Solana (SOL) [Member] Tron (TRX) [Member] USD Tether (USDT) [Member] Ripple (XRP) [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Statement of Income Location Balance [Axis] Income Other [Member] Short-Term Debt, Type [Axis] Marizyme Notes [Member] Chembio diagnostics [Member] Scenario [Axis] Until January 20, 2025 [Member] Securities Purchase Agreement [Member] Title and Position [Axis] Alpha Capital [Member] Series C Warrants [Member] Series C Warrant [Member] Class of Warrant or Right [Axis] Pre Funded Warrants [Member] Common Stock Warrants [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Weighted Average [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Term [Member] Measurement Input, Expected Dividend Rate [Member] Debt Instrument [Axis] 2022 Senior Convertible Debenture [Member] 2024 Alpha Debenture [Member] Alpha Capital Other Third Parties [Member] 2024 Chen Debenture Member 2025 Convertible Note [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Convertible Debt [Member] Award Type [Axis] Upfront Payment [Member] License Agreement [Member] Sponsored Research and License Agreement [Member] University of Louisville Research Foundation [Member] License and Sponsored Research Agreements [Member] Phase 1 Clinical Trial [Member] Phase 2 Clinical Trial [Member] Phase 3 Clinical Trial [Member] Product and Service [Axis] Licensed Product Sales [Member] Sponsored Research Agreements And License [Member] Co Development Agreement [Member] Faraday Subscription Agreement [Member] Investor [Member] Legal Firm [Member] Advisor [Member] Common Stock Purchase Agreement [Member] Yi Hua Chen [Member] Series A-2 and A-3 Convertible Preferred Stock [Member] Plan Name [Axis] 2020 Stock Incentive Plan [Member] General and Administrative Expense [Member] Research and Development Expense [Member] Compensatory Warrant Activity [Member] Noncompensatory Equity Classified Warrants [Member] Placement Agent Warrants [Member] Non Compensatory Warrant Activity [Member] Employees and Non-employee Service Provider [Member] Sale of Stock [Axis] Private Placement [Member] Lead Investor Agreement [Member] Executive Committee [Member] Chief Executive Officer [Member] President [Member] Master Service Agreement [Member] Faraday Future Global Partners [Member] Senior Convertible Debenture [Member] Convertible Debenture [Member] Segment Reporting Expense Information [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Alpha Capital Anstalt [Member] Entrusted Investment Agreement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Entity Listing, Par Value Per Share Auditor Firm ID Auditor Opinion [Text Block] Auditor Name Auditor Location Statement [Table] Statement [Line Items] ASSETS Current assets Cash and cash equivalents Digital assets Prepaid expenses and other current assets Short-term notes receivable, net of allowance for credit losses of $4.6 million and $360,000 at December 31, 2025 and 2024, respectively Total current assets Intangible assets Other assets Total non-current assets Total Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable Related party payable Accrued expenses and other current liabilities Warrant liabilities Convertible debt Total current liabilities Commitments and Contingencies (Note 10) Stockholders’ Equity Preferred stock, value Common stock, $0.001 par value; 225,000,000 shares authorized; 5,160,383 and 736,431 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively Additional paid-in capital Accumulated deficit Total Stockholders’ Equity Total Liabilities & Stockholders’ Equity Short-term note receivables net of allowance for credit losses Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] EXPENSES General and administrative Research and development Credit loss expense - short-term note receivable Total expenses LOSS FROM OPERATIONS OTHER EXPENSE (INCOME), NET Gain on change in fair value of warrant liabilities Gain on change in fair value of derivative liabilities Gain on change in fair value of convertible debt Interest expense Interest income Loss on issuance of convertible debt Net loss on digital assets Gain on voluntary conversion of convertible debt into common stock Loss on debt extinguishment Loss on monthly redemptions of convertible debt into common stock Gain on settlements of accounts payable Other expense (income), net Total other expense (income), net LOSS BEFORE PROVISION FOR INCOME TAXES PROVISION FOR INCOME TAXES NET LOSS FROM CONTINUING OPERATIONS DISCONTINUED OPERATIONS Loss on disposal of discontinued operations, net of tax LOSS FROM DISCONTINUED OPERATIONS NET LOSS Deemed dividend arising from preferred stock and warrant down-round provision Net loss attributable to shareholders Net loss per common share, basic - continuing operations Net loss per common share, diluted - continuing operations Net loss per common share, basic - discontinued operations Net loss per common share, diluted - discontinued operations Total net loss per common share, basic Total net loss per common share, diluted Weighted-average number of shares outstanding, basic Weighted-average number of shares outstanding, diluted Beginning balance, value Balance, shares Issuance of common stock for the conversion of Series A-2 preferred shares Issuance of common stock for the conversion of Series A-2 preferred shares, shares Stock-based compensation Issuance of Series A-3 preferred shares upon closing of private placement Issuance of Series A-3 preferred shares upon closing of private placement, shares Issuance of Series B preferred shares upon closing of private placement Issuance of Series B preferred shares upon closing of private placement, shares Issuance of common stock and warrants upon closing of private placement Issuance of common stock and warrants upon closing of private placement, shares Issuance of common stock for the conversion of Series A-3 preferred shares Issuance of common stock for the conversion of Series A-3 preferred shares, shares Net loss Issuance of common stock and prefunded warrants in public offering Issuance of common stock and prefunded warrants in public offering, shares Issuance of Series A-2 preferred shares upon closing of private placement Issuance of Series A-2 preferred shares upon closing of private placement, shares Voluntary conversion of convertible debt into preferred stock Voluntary conversion of convertible debt into preferred stock, shares Voluntary conversion of convertible debt into common stock Voluntary conversion of convertible debt into common stock, shares Redemptions of convertible debt into common stock Redemptions of convertible debt into common stock, shares Fair value of warrant modification for professional services Fair value of warrants reclassified to liabilities from equity Fair value of warrants reclassified to equity from liabilities Stock issued upon partial exercise of warrants Stock issued upon partial exercise of warrants, shares Restricted share settlements issued to former Board members Restricted share settlements issued to former Board members, shares Issuance of rounded shares as a result of the reverse stock split Issuance of rounded shares as a result of the reverse stock split, shares Ending balance, value Balance, shares Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] CASH FLOWS FROM OPERATING ACTIVITIES Loss from discontinued operations, net of tax Loss from continuing operations Adjustments to reconcile loss from continuing operations to net cash used in operating activities: Stock-based compensation Change in fair value of warrant liabilities Change in fair value of derivative liabilities Gain on voluntary conversion of convertible debt Legal expenses deducted from issuance of convertible debt Issuance of common stock to consultant Provision for credit losses of short-term note receivable Accrued interest on short-term note receivable Interest expense Payments made with digital assets Accretion of discount on convertible debt Loss on issuance of convertible debt Gain on settlement of accounts payable Loss on change in fair value of convertible debt Fair value of warrant modification for professional services Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable Accrued expenses and other current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES:  Issuance of short-term note receivable  Purchase of digital assets  Sales of digital assets Purchase of intangible assets Net cash provided by investing activities - discontinued operations Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from the issuance of convertible debt Net Proceeds from issuance of common shares and preferred shares in private placement - related party Proceeds from issuance of common shares and prefunded warrants in public offering Repayment of convertible debt Repayment of promissory notes Proceeds from warrant exercises Proceeds from issuance of promissory notes Net cash provided by financing activities - continuing operations Net cash provided by financing activities - discontinued operations Net cash provided by financing activities Net change in cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents- end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Interest Taxes NONCASH FINANCING AND INVESTING ACTIVITIES: Voluntary conversion of convertible debt into preferred stock Monthly redemption of convertible debt into common stock Voluntary conversion of convertible debt into common stock Deemed dividend arising from warrant and preferred shares down-round provision Exchange of derivative liability for warrant and convertible debt Restricted share settlements issued to former board members Warrants reclassified to equity from liabilities Warrants reclassified to liabilities from equity Issuance of warrants to placement agent Issuance of common stock for the conversion of Series A-2 and Series A-3 preferred shares Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Equity Awards Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Aggregate Available Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] Material Cybersecurity Incident [Abstract] Material Cybersecurity Incident Nature [Text Block] Material Cybersecurity Incident Scope [Text Block] Material Cybersecurity Incident Timing [Text Block] Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block] Material Cybersecurity Incident Information Not Available or Undetermined [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES LIQUIDITY AND GOING CONCERN Goodwill and Intangible Assets Disclosure [Abstract] DIGITAL ASSETS Schedule Of Digital Asset Activity Realized gains Realized loss Unrealized loss Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES AND OTHER CURRENT ASSETS Receivables [Abstract] SHORT-TERM NOTES RECEIVABLE Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS Payables and Accruals [Abstract] ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Warrant Liabilities WARRANT LIABILITIES Debt Disclosure [Abstract] CONVERTIBLE DEBT PROMISSORY NOTES Earnings Per Share [Abstract] EARNINGS (LOSS) PER SHARE Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Research And License Agreements RESEARCH AND LICENSE AGREEMENTS Equity [Abstract] STOCKHOLDERS’ EQUITY Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Segment Reporting [Abstract] SEGMENT INFORMATION Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENTS Corporate History Basis of Presentation Principles of Consolidation Discontinued Operations Accounting Estimates Related Parties and Related Party Transactions Reverse Stock Split Cash and Cash Equivalents Digital Assets General and Administrative Expenses Software Capitalization Research and Development Patent Costs Derivative Financial Instruments and Warrant Liabilities Fair Value Measurements Fair Value of Financial Instruments Stock-Based Compensation Income Taxes Recently Adopted Accounting Standards Recently Issued Accounting Standards Not Yet Adopted SCHEDULE OF CRYPTO ASSET HOLDINGS SCHEDULE OF DIGITAL ASSET ACTIVITY SCHEDULE OF FAIR VALUE MEASUREMENTS SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF SHORT-TERM NOTE RECEIVABLE SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF FAIR VALUE OF HIERARCHY FOR WARRANT LIABILITIES SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] SCHEDULE OF RESERVED SHARES SCHEDULE OF OUTSTANDING PREFERRED STOCK SCHEDULE OF STOCK OPTION ACTIVITY SCHEDULE OF NON COMPENSATORY WARRANT ACTIVITY SCHEDULE OF SEGMENT INFORMATION SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE SCHEDULE OF UNRECOGNIZED TAX BENEFITS SCHEDULE OF UNRECOGNIZED TAX BENEFITS SCHEDULE OF UNRECOGNIZED TAX BENEFITS SCHEDULE OF INCOME TAX NET OF REFUNDS Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Voting interests acquired Proceeds from issuance of common stock Net proceeds Issuance costs Net proceeds from the Offerings Number of shares forfeit Reverse stock split Selling, General and Administrative Expense [custom:OperatingExpensesPercentage] Cash Accumulated deficit Restricted cash equivalents Repayments of short-term debt Proceeds from sale of equity Proceeds from other equity Net proceeds from the offering Crypto Asset, Holding [Table] Crypto Asset, Holding [Line Items] Crypto asset number of units Crypto asset cost basis Crypto asset fair value Balance at December 31, 2024 Additions Dispositions Gains Losses Payments made but uncleared Balance at December 31, 2025 Fair Value, off-Balance-Sheet Risk [Table] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Assets Money Market funds Digital Assets Total Assets Liabilities Convertible Debt Warrant Liabilities Total Liabilities Prepaid consulting Prepaid insurance Prepaid legal Other current assets Prepaid expenses and other current assets Short-term note receivable - Marizyme Less allowance for credit losses Short-term notes receivable Short-Term Debt [Table] Short-Term Debt [Line Items] Principal amount Accrued interest Accrued interest on short-term note receivable Interest rate Expected credit losses Disposal Groups, Including Discontinued Operations [Table] Net cash consideration Proceeds from sale of business Escrow deposit Escrow deposits related to property sales Loss on disposal of discontinued operations License fees Credit card Professional fees Vacation Accrued expenses and other current liabilities Class of Warrant or Right [Table] Warrants exercise price Warrants to purchase common shares Warrants outstanding Gain (loss) on change in fair value of warrant liabilities Fair value of warrants Fair value of warrants reclassified from equity Fair value of warrants reclassified to equity Number of Shares, Warrants Outstanding Beginning Weighted Average Exercise Price Per Share Warrants Outstanding Beginning Range of Exercise Price, Beginning Weighted - Average Remaining Life (Years) Outstanding Number of Shares, Warrants Granted Weighted Average Exercise Price Per Share Warrants Granted Range of Exercise Price, Granted Weighted - Average Remaining Life (Years) Granted Number of Shares, Warrants Exercised Weighted Average Exercise Price Per Share Warrants Exercised Range of Exercise Price, Exercised Number of Shares, Reclassified from equity Weighted Average Exercise Price Per Share, Reclassified from equity Range of Exercise Price, Reclassified from equity Number of Shares, Reclassified to equity Weighted Average Exercise Price Per Share, Reclassified to equity Range of Exercise Price, Reclassified to equity Weighted - Average Remaining Life (Years) Reclassified to equity Number of Shares, Warrants Expired Weighted Average Exercise Price Per Share Warrants Expired Range of Exercise Price, Expired Number of Shares, Warrants Outstanding Ending Weighted Average Exercise Price Per Share Warrants Outstanding Ending Range of Exercise Price, Ending Number of Shares, Warrants Exercisable Weighted Average Exercise Price Per Share Warrants Exercisable Range of Exercise Price, Exercisable Weighted-Average Remaining Life (Years) Exercisable Class of Warrant or Right [Line Items] Warrants with no expiration Platform Operator, Crypto Asset [Table] Platform Operator, Crypto Asset [Line Items] Common stock warrant liabilities, Beginning balance Granted Exercised Fair value of warrants reclassified to equity Gain on change in fair value of warrant liabilities Common stock warrant liabilities, Ending balance Business Combination [Table] Business Combination [Line Items] Warrants outstanding, measurement input Term of warrants (in years) Senior convertible debenture rate Principal amount Purchase price Maturity date Conversion price per share Issued and outstanding shares percentage Redeemable debt Conversion rate Interest rate Debt instrument fair value Gain loss on extinguishment of debt Warrant exercise price Shares of common stock conversion Redemption amounts in common stock Weighted average conversion price per share Amortization of debt discount Voluntary conversion of convertible debt Number of shares issued Outstanding amount Cash purchase price payment Share price Debt term Class of warrant Carrying amount Purchase price of warrants Fair value of option Fair value of embedded derivative features Debt conversion amount Loss on voluntary conversion Proceeds to repay the outstanding principal and accrued interest Debt conversion Proceeds from issuance of debt Fair value of warrant Original issue discount Other expense Fair value of convertible securities Proceeds from issuance of convertible note Issuance cost Change in fair value of convertible note Notes payable Proceeds from short term debt Repayments of outstanding promissory notes Interest expense Net loss attributable to shareholders Basic weighted-average common shares outstanding Dilutive potential shares issuable from preferred stock, convertible debt, stock options and warrants Diluted weighted-average common shares outstanding Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total common stock equivalents Litigation paid Payments to settle the outstanding claim Research and Development, Contract to Perform for Others [Table] Reimbursement of patent License costs Reimbursement of research expenses License and sponsored research agreement terms Milestone payment Cumulative sales Cumulative sales Revenue Upfront license fee Research and development expenses Proceeds from convertible debt Patent costs Marketing approval expenses Regulatory marketing approval, expenses Shortfall payments Marizyme agreement terms Exclusivity Fee Debt funded to Marizyme Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Total Preferred stock, conversion price Preferred stock, common stock equivalent Number of shares, options outstanding, beginning Weighted average exercise price, beginning Range of exercise price, options outstanding, beginning Weighted average remaining life (Years) Number of shares, options granted Weighted average exercise price, granted Number of shares, options expired Weighted average exercise price, expired Number of shares, options forfeited Weighted average exercise price, forfeited Range of exercise price, options forfeited Number of shares, options outstanding, ending Weighted average exercise price, ending Range of exercise price, options outstanding, ending Number of shares, options exercisable (vested) Weighted average exercise price, options exercisable (vested) Range of exercise price, options exercisable (vested) Weighted average remaining life (Years), exercisable (vested) Number of shares, warrants non-exercisable Weighted average exercise price, options non-exercisable (non-vested) Range of exercise price, options non-exercisable (non-vested) Weighted average remaining life (Years), Non-exercisable (non-vested) Range of Exercise Price, Beginning Weighted Average Remaining Life (Years) - outstanding Number of Shares, Warrants Exercised Weighted Average Exercise Price Per Share Warrants, Exercised Number of Shares, Warrants Expired Weighted Average Exercise Price Per Share Warrants, Expired Range of Exercise Price, Expired Number of Shares, Warrants Reclassified to liabilities Weighted Average Exercise Price Per Share Warrants, Reclassified to liabilities Range of Exercise Price, Reclassified to liabilities Number of Shares, Warrants Forfeited Weighted Average Exercise Price Per Share Warrants, Forfeited Range of Exercise Price, Ending Number of Shares, Warrants Exercisable Weighted Average Exercise Price Per Share Exercisable Range of Exercise Price, Exercisable Weighted Average Remaining Life (Years) Exercisable Number of Shares, Warrants Non-exercisable Weighted Average Exercise Price Per Share Non-Exercisable Range of Exercise Price, Non-Exercisable Number of Shares, Warrants, Granted Weighted Average Exercise Price Per Share Warrants, Granted Range of Exercise Price, Granted Weighted Average Remaining Life (Years) - outstanding, Granted Number of Shares, Warrants, Prefunded investor warrants issued Weighted Average Exercise Price Per Share Warrants, Prefunded investor warrants issued Range of Exercise Price, Prefunded investor warrants issued Number of Shares, Warrants, Prefunded investor warrants exercised Weighted Average Exercise Price Per Share Warrants, Prefunded investor warrants exercised Range of Exercise Price, Prefunded investor warrants exercised Range of Exercise Price, Exercised Number of Shares, Warrants, Reclassified to liabilities Range of Exercise Price, Reclassified to liabilities Number of Shares, Warrants, Reclassified from liabilities Weighted Average Exercise Price Per Share Warrants, Reclassified from liabilities Range of Exercise Price, Reclassified from liabilities Range of Exercise Price, Expired Number of Shares, Warrants Forfeited Range of Exercise Price, Forfeited Weighted Average Exercise Price Per Share Warrants, Exercisable Weighted Average Remaining Life (Years) - Exercisable Number of Shares Warrants, Non-Exercisable Weighted Average Exercise Price Per Share Warrants, Non-Exercisable Range of Exercise Price, Non-exercisable Shares reserved for future issuance Number of shares issued and sold Common stock purchase price per share Value of shares sold Grant date fair value of shares Warrant to purchase shares of common stock Exercise price Warrants outstanding Value of shares available for sale Preferred stock, shares designated Share price Gross proceeds from issuance of shares Offering expenses Net proceeds Shares issued upon debt exchange Debt amount exchanged Common shares issuable upon conversion Conversion price, per share Preferred stock converted Common stock issued upon conversion Floor price, per share Share price, per share Options outstanding Compensation cost Unrecognized compensation cost Number of warrants issued Warrant exercised Deemed dividend Warrants exercised Weighted average exercise price per share warrants reclassified to liabilities Fair value of warrants reclassified to liabilities from equity Related Party Transaction [Table] Investments Proceeds from investor Transition services charged Consulting services fee Purchase Price Debt conversion shares issued Weighted average exercise price Outstanding accrued interest Cumulative proceeds from issuance of warrants Warrant to purchase shares of common stock Warrants shares Fair value of warrants on grant date Warrant liabilities Gain on change in fair value of warrant liabilities Total other expense, net  Net loss Number of operating segment Number of reportable segment Domestic Foreign Statutory federal income tax rate Tax Jurisdiction of Domicile [Extensible Enumeration] Statutory federal income tax rate, Amount State taxes, net of federal tax benefit State taxes, net of federal tax benefit, Amount Foreign Tax Effects Foreign Tax Effects, Amount NOL expiration Effect of Changes in Tax Laws or Rates Enacted in the Current Period Effect of Changes in Tax Laws or Rates Enacted in the Current Period, Amount Effect of Cross-Border Tax Laws Effect of Cross-Border Tax Laws, Amount Tax credit Research and development tax credits Research and development tax credits, Amount Change in FV of warrant liability Tax impact of convertible debenture Tax impact of divestiture Change in valuation allowance Change in valuation allowance, Amount Non-deductible expenses Non-deductible expenses, Amount Stock compensation Stock compensation, Amount Changes in Unrecognized Tax Benefits Changes in Unrecognized Tax Benefits, Amount Tax impact of section 382 attribute forfeiture Tax impact of section 382 attribute forfeiture, Amount True-up True-up, Amount Income taxes provision (benefit) Income taxes provision (benefit), Amount US Federal US State US Foreign Total current provision US Federal US State US Foreign Total deferred benefit Change in valuation allowance Deferred tax assets Net operating loss Research and development credits Accrued expenses Stock compensation Unrealized loss on digital assets Provision for losses on notes receivable Research and development expenses Net deferred income tax assets Valuation allowance Deferred tax asset, net of allowance Gross unrecognized tax benefits at the beginning of the year Increases (decreases) related to current year positions Increases (decreases) related to prior year positions Expiration of unrecognized tax benefits Gross unrecognized tax benefits at the end of the year Federal State Foreign Total cash paid for income taxes, net of refunds U.S. federal operating loss carryforwards State operating loss carryforwards Unrecognized tax benefits Subsequent Event [Table] Subsequent Event [Line Items] Conversion of stock shares converted Conversion price Convertible notes outstanding repaid Shares consideration Bid price Warrant liabilities current. Accrued interest on short-term note receivable. Marizyme Notes [Member] Chembio diagnostics [Member]. Until January 20, 2025 [Member] Accrued license fees. Accrued credit card. Warrant Liabilities [Text Block] Series C Warrants [Member] Securities Purchase Agreement [Member] Alpha Capital [Member] The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan. Gain (loss) on change in fair value of warrant liabilities. Series A-2 Convertible Preferred Stock [Member] Pre Funded Warrants [Member] Common Stock Warrants [Member] Share based compensation arrangement by share based payment award non option equity instruments reclassified from equity. Share based compensation arrangement by share based payment award non option equity instruments reclassified to equity. Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization. Weighted average exercise price per share warrants exercised. Share based compensation arrangement by share based payment award non option equity instruments grants in period weighted average reclassified equity price. Share based compensation arrangement by share based payment award non option equity instruments reclassified to equity price. Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price. Weighted average exercise price per share exercisable (vested). Range of exercise price. Range of exercise price granted. Range of expired price. Range of exercise price, exercisable (vested). Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Credit loss expense short term note receivable. Loss gain on change in fair value of warrant liabilities. Loss on issuance of convertible debt. Gain loss on voluntary conversion of convertible debt into common stock. Loss on monthly redemptions of convertible debt into common stock. Gain on settlements of accounts payable. Range of exercise price reclassified from equity. Range of exercise price reclassified to equity. Share based compensation arrangement by share based payment award non option equity instruments granted exercisable weighted average remaining contractual term 1. Share based compensation arrangement by share based payment award non option equity instruments equity weighted averag remaining contractual term 1. Range of exercise price excerised. Fair value of warrant liabilities on date of granted. 2022 Senior Convertible Debenture [Member] Purchase price. Percentage of stock issued and outstanding. Debt redemption amount in common stock. Weighted average conversion price per share. Gain on change in fair value of convertible debt. 2024 Alpha Debenture [Member] Alpha Capital Other Third Parties [Member] Voluntary conversion of convertible debt. 2024 Chen Debenture Member StockIssuedDuringPeriodValueIssuanceOfSeriesA2PreferredSharesUponClosingOfPrivatePlacement Issuance of Series A-2 preferred shares upon closing of private placement, shares. Number of shares issued during the period as a result of the voluntary conversion of convertible debt into preferred stock, shares. Number of shares issued during the period as a result of the voluntary conversion of convertible debt into preferred stock. Redemptions of convertible debt into common stock, value. Redemptions of convertible debt into common stock, shares. Amount of increase in additional paid in capital (APIC) resulting from fair value of warrants reclassified to liabilities from equity. Amount of increase in additional paid in capital (APIC) resulting from fair value of warrants reclassified to equity from liabilities. Stock issued during period values reverse stock splits. Series A-3 Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Stock Issued During Period Value Issuance Of Series A-2 Preferred Shares Conversion. Stock issued during period shares issuance of Series A-2 Preferred Shares Conversion. Issuance of Series A-3 preferred shares upon closing of private placement. Issuance of Series A-3 preferred shares upon closing of private placement, shares. Issuance of Series B preferred shares upon closing of private placement. Issuance of Series B preferred shares upon closing of private placement, shares. Stockissued during period value issuance of common stock and warrants upon closing of private placement. Stockissued during period share issuance of common stock and warrants upon closing of private placement. 2025 Convertible Note [Member] Change in fair value of convertible note. Gain on voluntary conversion of convertible debt. Legal expenses deducted from issuance of convertible debt. Issuance of common stock to consultant. Accretion of discount on convertible debt. Gain loss on issuance of convertible debt. Fair value of warrant modification for professional services. Research And License Agreements [Text Block] Reimbursement of patent. Upfront Payment [Member] License Agreement [Member] License costs. Voluntary conversion of convertible debt into common stock. Monthly redemptions of convertible debt into common stock. Deemed dividend arising from warrant downround provision. Reimbursement of research expenses. Sponsored Research and License Agreement [Member] University of Louisville Research Foundation [Member] Voluntary conversion of convertible debt into preferred stock. Agreement term payment, description. Exchange of derivative liability for warrant and convertible debt. Restricted share settlements issued. Milestone payment. License and Sponsored Research Agreements [Member] Warrants reclassified to liabilities from equity. Issuance of warrants to placement agent. Phase 1 Clinical Trial [Member] Phase 2 Clinical Trial [Member] Phase 3 Clinical Trial [Member] Cumulative sales one. Licensed Product Sales [Member] Cumulative sales. Upfront license fee. Sponsored Research Agreements And License [Member] NanoSynex, Ltd. [Member] Amendment And Settlement Agreement [Member] :Reverse Stock Split [Policy Text Block] Patent costs. Regulatory marketing approval, expenses. Regulatory marketing approval expenses one. Shortfall payments. Co Development Agreement [Member] Loss on change in fair value of short-term note receivable. Subscription Agreement [Member] Common Stock Purchase Agreement [Member] Operating expenses percentage. IR Agency LLC [Member] Patent Costs [Policy Text Block] Derivative Financial Instruments and Warrant Liabilities [Policy Text Block] Disclosure of accounting policy pertaining to accounting standards updates not yet adopted Yi Hua Chen [Member] Series A-2 and A-3 Convertible Preferred Stock [Member] Debt instrument floor price. 2020 Stock Incentive Plan [Member] Employees and Non-employee Service Provider [Member] Money market funds fair value disclosure. Warrant liabilities fair value disclosures. Prepaid consulting. Prepaid legal. Weighted- average remaining contractual life (in years), options non-exercisable (non-vested). Compensatory Warrant Activity [Member] Number of shares, warrants non-exercisable (non-vested). Weighted average exercise price per share warrants forfeited. Weighted average exercise price per share non-exercisable (non-vested). Range Of Exercise Price Outstanding. Range of exercise price expired. Range of exercise price, non-exercisable (non-vested). Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one. Share based compensation arrangement by share based payment award non option equity instruments reclassified to liabilities. Share based compensation arrangement by share based payment award non option equity instruments reclassified to liabilities in period weighted average exercise price. Range of exercise price, reclassified to liabilities. Noncompensatory Equity Classified Warrants [Member] Deemed dividend arising from warrant modification. Fair value of warrants reclassified to liabilities from equity. Non Compensatory Warrant Activity [Member] Share based compensation arrangement by share based payment award non option equity instruments non exercisable number. Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average vested non exercise price. Range of exercise price exercisable granted. Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted averag granted remaining contractual term 1. Share based compensation arrangement by share based payment award non option equity instruments prefunded investor warrants issued. Share based compensation arrangement by share based payment award non option equity instruments prefunded investor warrants exercised. Share based compensation arrangement by share based payment award non option equity instruments reclassified from liabilities. Share based compensation arrangement by share based payment award non option equity instruments prefunded investor warrants issued in period weighted average exercise price Share based compensation arrangement by share based payment award non option equity instruments prefunded investor warrants exercised in period weighted average exercise price. Share based compensation arrangement by share based payment award non option equity instruments reclassified from liabilities in period weighted average exercise price. Range of exercise price exercisable prefunded investor warrants issued. Range of exercise price exercisable prefunded investor warrants exercised. Range of exercise price exercisable excercised. Range of exercise price exercisable reclassified to liabilities. Range of exercise price exercisable reclassified from liabilities. Share based compensation arrangement by share based payment award non option equity instruments expired in range of exercise price. Nonoption equity instrument forfeited in range of exercise price. Master Service Agreement [Member] Faraday Future Global Partners [Member] Faraday Future Intelligent Electric Inc [Member] Senior Convertible Debenture [Member] Convertible Debenture [Member] Gain on change in fair value of warrants. Fair value of warrant liabilities current. Series C Warrant [Member] Stock issued during period value issuance of series A3 preferred shares conversion. Stock issued during period shares issuance of series A3 preferred shares conversion. Payments made with digital assets. Warrants reclassified to equity from liabilities. Software Capitalization [Policy Text Block] Cardano ADA (ADA) [Member] Native BNB (BSC) [Member] Bitcoin (BTC) [Member] Dogecoin (DOGE) [Member] Ethereum (ETH) [Member] ChainLink (LINK) [Member] Solana (SOL) [Member] Tron (TRX) [Member] USD Tether (USDT) [Member] Ripple (XRP) [Member] Summary of Warrant Activity [Table Text Block] Change in fair value digital asset. Loss on sales digital asset. Loss on change in fair value of convertible debt. Accrued interest. Effective income tax rate reconciliation non operating loss expiration. Effective income tax rate reconciliation tax impact of convertible debenture. Effective income tax rate reconciliation tax impact of divestiture. Tax impact of section 382 attribute forfeiture. Effective income tax rate true-up. Income tax reconciliation tax impact of attribute forfeiture. Income tax reconciliation true up. Expiration of unrecognized tax benefits. Schedule O fIncome Tax Refunds [Table Text Block] Alpha Capital Anstalt [Member] Entrusted Investment Agreement [Member] Fair value measurement with unobservable inputs reconciliation recurring basis liability exercised. Share based compensation shares authorized under stock option plans exercise price range forfeited options weighted average exercise price1. Share based compensation shares authorized under stock option plans exercise price range Non-exercisable options weighted average exercise price1. Faraday Subscription Agreement [Member] Legal Firm [Member] Advisor [Member] Placement Agent Warrants [Member] Member of Baord [Member] Income Other [Member] General and Administrative Expense [Member] Research and Development Expense [Member] Related Parties and Related Party Transactions [Policy Text Block] Realized gains. Realized losses. Unrealized loss. Bid price. Segment Reporting Expense Information [Member] Domestic Tax Jurisdiction [Member] Assets, Current Assets, Noncurrent Assets [Default Label] Liabilities, Current Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) LossGainOnChangeInFairValueOfWarrantLiabilities Derivative, Gain (Loss) on Derivative, Net GainOnChangeInFairValueOfConvertibleDebt Investment Income, Interest Crypto Asset, Realized Gain (Loss), Operating GainOnSettlementsOfAccountsPayable Other Nonoperating Income (Expense) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Warrant, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount Net Income (Loss) Available to Common Stockholders, Basic Equity, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Stock Issued During Period, Shares, Reverse Stock Splits GainOnVoluntaryConversionOfConvertibleDebt Interest Expense, Operating and Nonoperating AccretionOfDiscountOnConvertibleDebt GainLossOnIssuanceOfConvertibleDebt LossOnChangeInFairValueOfConvertibleDebt FairValueOfWarrantModificationForProfessionalServices Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments for (Proceeds from) Loans Receivable Payment for Acquisition, Crypto Asset Payments to Acquire Intangible Assets Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Repayments of Convertible Debt Cash Provided by (Used in) Financing Activity, Continuing Operation Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation VoluntaryConversionOfConvertibleDebtIntoPreferredStock VoluntaryConversionOfConvertibleDebtIntoCommonStock DeemedDividendArisingFromWarrantAndPreferredSharesDownroundProvision ExchangeOfDerivativeLiabilityForWarrantAndConvertibleDebt Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Crypto Asset, Sale ChangeInFairValueDigitalAsset LossOnSalesDigitalAsset Crypto Asset, Payment for Service WarrantLiabilitiesFairValueDisclosures Accrued Liabilities, Current ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice RangeOfExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToEquity Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Secured Debt Debt Instrument, Interest Rate, Stated Percentage Interest Expense, Debt CumulativeSales Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Range of exercise price outstanding RangeOfExercisePriceExpired RangeOfExercisePriceExercisableGranted RangeOfExercisePriceExercisableExcercised Range of exercise price exercisable reclassified to liabilities ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice Shares Issued, Price Per Share FairValueOfWarrantsReclassifiedToLiabilitiesFromEquity FairValueOfWarrantLiabilitiesCurrent GainOnChangeInFairValueOfWarrants Effective Income Tax Rate Reconciliation, Tax Credit, Percent Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Effective Income Tax Rate Reconciliation, Percent Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Income Tax Paid, Foreign, after Refund Received Income Taxes Paid